References
1. Saddi V, Beggs S, Bennetts B, et al. Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade’s experience. Orphanet J Rare Dis. 2017;12(1):133.
2. Griese M, Seidl E, Hengst M, et al. International management platform for children’s interstitial lung disease (chILD-EU). Thorax.2018;73(3):231-239.
3. Torrent-Vernetta A, Gaboli M, Castillo-Corullon S, et al. Incidence and Prevalence of Children’s Diffuse Lung Disease in Spain. Arch Bronconeumol. 2022;58(1):22-29.
4. Deutsch GH, Young LR, Deterding RR, et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med. 2007;176(11):1120-1128.
5. Fan LL, Dishop MK, Galambos C, et al. Diffuse Lung Disease in Biopsied Children 2 to 18 Years of Age. Application of the chILD Classification Scheme. Ann Am Thorac Soc. 2015;12(10):1498-1505.
6. Griese M. Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases. J Clin Med. 2022;11(6).
7. Nathan N, Griese M, Michel K, et al. Diagnostic workup of childhood interstitial lung disease. Eur Respir Rev. 2023;32(167).
8. Cunningham S, Jaffe A, Young LR. Children’s interstitial and diffuse lung disease. Lancet Child Adolesc Health. 2019;3(8):568-577.
9. Seidl E, Schwerk N, Carlens J, et al. Healthcare resource utilisation and medical costs for children with interstitial lung diseases (chILD) in Europe. Thorax. 2022;77(8):781-789.
10. Seidl E, Schwerk N, Carlens J, et al. Acute exacerbations in children’s interstitial lung disease. Thorax. 2022;77(8):799-804.
11. Casey AM, Deterding RR, Young LR, Fishman MP, Fiorino EK, Liptzin DR. Overview of the ChILD Research Network: A roadmap for progress and success in defining rare diseases. Pediatr Pulmonol.2020;55(7):1819-1827.
12. Casamento K, Laverty A, Wilsher M, et al. Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience. Orphanet J Rare Dis. 2016;11:42.
13. Cunningham S, Gilbert C, Schwerk N, Ch ICRCMC, Members of the Ch ICRCMC. The European research collaboration for Children’s Interstitial Lung Disease (ChILDEU) ERS Clinical Research Collaboration. Eur Respir J. 2018;52(6).
14. Young LR, Trapnell BC, Mandl KD, Swarr DT, Wambach JA, Blaisdell CJ. Accelerating Scientific Advancement for Pediatric Rare Lung Disease Research. Report from a National Institutes of Health-NHLBI Workshop, September 3 and 4, 2015. Ann Am Thorac Soc. 2016;13(12):385-393.
15. Young LR, Nevel RJ, Casey AMH, et al. The National Registry for Childhood Interstitial and Diffuse Lung Diseases: An Initial Report from the ChILD Research Network. B97. IMPORTANCE OF LONGITUDINAL COHORT STUDIES IN PEDIATRICS. Am J Respir Crit Care Med. A4191-A4191.
16. PA Harris RT, R Thielke, J Payne, N Gonzalez, JG Conde. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
17. PA Harris RT, BL Minor, V Elliott, M Fernandez, L O’Neal, L McLeod, G Delacqua, F Delacqua, J Kirby, SN Duda, REDCap Consortium. The REDCap consortium: Building an international community of software partners.J Biomed Inform. 2019;95:103208.
18. Fan LL, Kozinetz CA. Factors influencing survival in children with chronic interstitial lung disease. Am J Respir Crit Care Med.1997;156(3 Pt 1):939-942.
19. Bureau USC. QuickFacts: Race and Hispanic Origin. 2020.
20. Griese M, Kappler M, Stehling F, et al. Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease.Orphanet J Rare Dis. 2022;17(1):289.
21. Deterding R, Young LR, DeBoer EM, et al. Nintedanib in children and adolescents with fibrosing interstitial lung diseases. European Respiratory Journal. 2022:2201512.